ALFA Finder| Revenue growth | 5.6% YoY for Q4FY26; 6.1% for full year FY26. |
|---|---|
| Margins | EBITDA margin at 20.3% in Q4FY26 vs 21.4% in Q4FY25. |
| Demand visibility | Strong Europe performance; stable US base business despite seasonality. |
Growth
FY26 revenue grew 6.1% YoY to ₹33,653 Cr; Europe grew 23.4% and Growth Markets 10% in FY26.
Outlook
Targets 7-8 marketed biosimilars in EU/UK/Canada by 2030; USD 150-175 Mn CAPEX for TheraNym Unit 2.
Risks
USA revenue declined 13% YoY in Q4 due to seasonality and lower transient product sales.
Earnings Call filed with NSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,796.40
- Market cap
- ₹1,04,335 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.7×Sector 43.8×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Business Update
Aurobindo Pharma disclosed that US FDA classified its Lannett facility inspection as Official Action Indicated (OAI). The company states there is no quantifiable financial or operational impact.
Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.